US Patent

US7858643 — Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Composition of Matter · Assigned to Agouron Pharmaceuticals LLC · Expires 2029-10-08 · 3y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors, specifically for treating abnormal cell growth disorders like cancers.

USPTO Abstract

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

Drugs covered by this patent

Patent Metadata

Patent number
US7858643
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-10-08
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Agouron Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.